Medical technology company Haemonetics has announced the full market release of its VASCADE MVP XL mid-bore venous closure system.
VASCADE MVP XL, the latest addition to the VASCADE portfolio, is now available for US hospitals.
The vascular closure system features collapsible disc technology and a proprietary resorbable collagen patch designed to ensure rapid haemostasis.
In June 2024, Haemonetics announced the limited market release of this mid-bore venous closure device after receiving pre-market approval from the US Food and Drug Administration in the spring. Since then, the device has been used by nearly 80 physicians across more than 30 hospitals for various procedures.
The limited market release followed the first procedure using the VASCADE MVP XL performed at the University of Alabama at Birmingham.
Haemonetics global hospital president Stew Strong said: “We received overwhelmingly positive feedback during our limited market release and we are excited to make VASCADE MVP XL available to physicians at all US hospitals as soon as possible.
“With our full market release underway and an ongoing clinical trial program to broaden the indications for this device to even larger access points, VASCADE MVP XL will complement our Interventional Technologies portfolio, and underscore our aspiration to be the go-to leader in vascular closure.”
The VASCADE MVP XL system incorporates 58% more collagen and a larger disc compared to the VASCADE MVP system.
It offers a robust closure solution for procedures that require 10-12F sheaths, including cryoablation, pulsed field ablation (PFA), and left atrial appendage closure (LAAC).
Haemonetics’ current VASCADE portfolio features the VASCADE system, tailored for small-bore femoral arterial and venous closure with standard 5-6/7F procedural sheaths.
It also includes the VASCADE MVP system, designed for mid-bore multi-access femoral venous closure with 6-12F ID procedural sheaths.
The VASCADE system was originally developed by Cardiva Medical, which was acquired by Haemonetics in 2021 for an upfront cash payment of $475m.
Recently, the medical technology company secured CE Mark certification for the SavvyWire Pre-Shaped Pressure Guidewire.
